|  | Kontermann, Roland (Hrsg.)
Therapeutic Proteins
Strategies to Modulate Their Plasma Half-lives
 1. Auflage Februar 2012
129,- Euro
2012. XVIII, 354 Seiten, Hardcover
95 Abb. (21 Farbabb.), 29 Tab.
- Handbuch/Nachschlagewerk -
ISBN 978-3-527-32849-9 - Wiley-VCH, Weinheim
Preis inkl. Mehrwertsteuer zzgl. Versandkosten.
|
Inhalt
Probekapitel
Index
| Jetzt kaufen   
E-Books sind auch über alle bekannten E-Book Shops erhältlich.
|
| Kurzbeschreibung
The world wide knowledge on how to modify therapeutic proteins in order to optimize their pharmacological potential. A must for all companies and research institutions working on the development of biopharmaceuticals.
Aus dem Inhalt
GENERAL INFORMATION
Half-life modulating strategies - an introduction (Roland Kontermann)
Pharmacokinetics and half-life protein of therapeutics (Bernd Meibohm)
HALF-LIFE EXTENSION THROUGH CHEMICAL AND POSTTRANSLATIONAL MODIFICATIONS
Half-life extension through PEGylation (Simona Jevsevar and Menci Kunstelj)
Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics
(Uli Binder and Arne Skerra)
Half-life extension through O-glyosylation (Fuad Fares)
Polysialic acid and polysialylation to modulate antibody pharmacokinetics (Antony Constantinou, Chen Chen and Mahendra P. Deonarain)
Half-life extension through HESylation (Thomas Hey, Helmut Knoller and Peter Vorstheim)
HALF-LIFE MODULATION INVOLVING RECYCLING BY THE NEONATAL FC RECEPTOR
The biology of FcRn (Jonghan Kim)
Half-life extension by fusion to the Fc region (Jalal A. Jazayeri and Graeme J Carroll)
Monomeric Fc fusion Technology: an approach to create long lasting clotting factors (Jennifer A. Dumont, Xiaomei Jei, Robert T. Peters, Alvin Luk, Glenn F. Pierce and Alan J. Bitonti)
The diverse roles of FcRn: implications for antibody engineering (Sally Ward and Raimund J. Ober)
Half-life extension by fusion to albumin (Hubert J. Metzner, Thomas Weimer and Stefan Schulte)
AlbudAb(TM) technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives (Christopher Herring and Oliver Schon)
Half-life extension by binding to albumin through an albumin-binding domain (Fredrik Frejd)
Half-life extension by binding to albumin through small molecules (Sabrina Trüssel, Joerg Scheuermann and Dario Neri)
HALF-LIFE EXTENSION WITH PHARMACEUTICAL FORMULATIONS
Half-life extension with pharmaceutical formulations: liposomes (Astrid Hartung and Gerd Bendas)
Half-life extension with pharmaceutical formulations: nanoparticles (Katharina Landfester)
|
|
|
|
